Mantle Cell Lymphoma

The Evolving Landscape of Mantle Cell Lymphoma

A look back at all the FDA news that occurred in the month of August.

Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the need to develop novel therapies in mantle cell lymphoma, including a study that explored the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors.

A new drug application (NDA) for acalabrutinib has been granted a priority review by the FDA for patients with previously-treated mantle cell lymphoma (MCL), according to AstraZeneca, the manufacturer of the highly selective, potent BTK inhibitor.

Acalabrutinib has been granted a breakthrough therapy designation by the FDA for patients with previously-treated mantle cell lymphoma (MCL), according to AstraZeneca, the manufacturer of the highly selective, potent BTK inhibitor.

Martin Dreyling, MD, discusses results of the phase II CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma.

Pembrolizumab has been approved by the European Commission for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.

A majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib, according to results from the phase II CHRONOS-1 trial.<br /> &nbsp;

A biologics license application has been submitted for axicabtagene ciloleucel (KTE-C19) as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Patients with lymphoma who are treated with brentuximab vedotin often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with brentuximab vedotin outweigh the risk of neuropathy.&nbsp;

Andre Goy, MD, highlights what researchers can expect next in the field of MCL in both the frontline and relapsed/refractory settings given the recent pivotal data from clinical trials.

The combination of rituximab, bendamustine, and low-dose cytarabine demonstrated a high complete response rate as an induction regimen for elderly patients with mantle cell lymphoma.